INDICATIONS ZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age. ZORYVE cream, 0.15%, is indicated for topical ...

Amlitelimab is effective at improving moderate to severe AD across all body regions, including the difficult-to-treat head and neck region.

Atopic dermatitis (AD) is a chronic disease that affects an increasing number of children and adults. The skin is dry and ...

Oncodermatology is evolving with nonsurgical approaches and immune checkpoint inhibitors, improving outcomes in aggressive ...

Among patients with moderate to severe atopic dermatitis, atopic comorbidities did not change the benefits seen with lebrikizumab, according to data published in Annals of Allergy, Asthma & Immunology ...

Most patients expressed an interest in understanding how environmental-climate factors affect their atopic dermatitis.

Sanofi has announced that its amlitelimab has shown positive results in the treatment of patients 12 years and older with ...

Amgen and Kyowa Kirin are pulling the plug on a collaboration the drugmakers launched in 2021 aimed at developing a treatment for the inflammatory skin disease atopic dermatitis.

A new study published in the Journal of the European Academy of Dermatology and Venerology showed that nemolizumab, an ...

Researchers at Ben-Gurion University of the Negev (BGU) have discovered that a gene long known for shaping the skin's ...

The core symptoms of atopic dermatitis — dry and cracked skin, itchiness, rashes on swollen skin, and oozing, crusting irritated skin — can appear anywhere on the body. The exact symptoms and severity ...

Amgen ends its rocatinlimab partnership, returning control to Kyowa Kirin, citing strategy changes, weaker Phase 3 results ...